Inhibikase Therapeutics, Inc. (IKT) stock
IKTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.38−0.07 (-4.83%)
Close on Nov 17, 2026Market cap $192.56MP/E –Yield –
Inhibikase Therapeutics total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Inhibikase Therapeutics's total debt was $0 at Dec 31, 2025. For fiscal 2025 it was $0, down 100.0% from the year before. The highest annual figure on record is $276.46K in fiscal 2020.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | -100.0% |
| FY2024 | Dec 31, 2024 | $110.52K | -26.4% |
| FY2023 | Dec 31, 2023 | $150.10K | +2.9% |
| FY2022 | Dec 31, 2022 | $145.84K | – |
| FY2021 | Dec 31, 2021 | $0 | -100.0% |
| FY2020 | Dec 31, 2020 | $276.46K | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | $0 | -100.0% |
| Q3 FY2025 | Sep 30, 2025 | $0 | -100.0% |
| Q2 FY2025 | Jun 30, 2025 | $37.94K | -75.1% |
| Q1 FY2025 | Mar 31, 2025 | $74.77K | -50.5% |
| Q4 FY2024 | Dec 31, 2024 | $110.52K | -26.4% |
| Q3 FY2024 | Sep 30, 2024 | $145.21K | -2.6% |
| Q2 FY2024 | Jun 30, 2024 | $152.22K | +2.9% |
| Q1 FY2024 | Mar 31, 2024 | $151.16K | +2.9% |
| Q4 FY2023 | Dec 31, 2023 | $150.10K | +2.9% |
| Q3 FY2023 | Sep 30, 2023 | $149.03K | +4.9% |
| Q2 FY2023 | Jun 30, 2023 | $147.97K | – |
| Q1 FY2023 | Mar 31, 2023 | $146.90K | -41.0% |
| Q4 FY2022 | Dec 31, 2022 | $145.84K | -41.4% |
| Q3 FY2022 | Sep 30, 2022 | $142.05K | -48.6% |
| Q4 FY2021 | Dec 31, 2021 | $0 | – |
| Q2 FY2021 | Jun 30, 2021 | $248.91K | – |
| Q1 FY2021 | Mar 31, 2021 | $248.91K | – |
| Q4 FY2020 | Dec 31, 2020 | $276.46K | – |
See a number that looks wrong?